{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:22:54Z","timestamp":1781241774085,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["RS-2023-00216446"],"award-info":[{"award-number":["RS-2023-00216446"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01395-6","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:47:06Z","timestamp":1761821226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5438-7819","authenticated-orcid":false,"given":"Suein","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8826-4136","authenticated-orcid":false,"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2758-8936","authenticated-orcid":false,"given":"Chae Hyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungpil","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Koshiaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghoon","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"1395_CR1","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412\u20137.","journal-title":"Blood"},{"key":"1395_CR2","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","volume":"113","author":"BM Weiss","year":"2009","unstructured":"Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113:5418\u201322.","journal-title":"Blood"},{"key":"1395_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00719-0","volume":"12","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV, Kumar S, Lonial S, Mateos MV. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 2022;12:129.","journal-title":"Blood Cancer J"},{"key":"1395_CR4","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1182\/blood-2013-08-520890","volume":"122","author":"A Dispenzieri","year":"2013","unstructured":"Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, et al. Smoldering multiple myeloma requiring treatment: time for a new definition?. Blood. 2013;122:4172\u201381.","journal-title":"Blood"},{"key":"1395_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1182\/blood.2024027065","volume":"145","author":"IM Ghobrial","year":"2025","unstructured":"Ghobrial IM, Chabrun F. Is it time to screen for multiple myeloma?. Blood. 2025;145:253\u20135.","journal-title":"Blood"},{"key":"1395_CR6","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1182\/blood-2010-04-277566","volume":"116","author":"G Bianchi","year":"2010","unstructured":"Bianchi G, Kyle RA, Colby CL, Larson DR, Kumar S, Katzmann JA, et al. Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood. 2010;116:2019\u201325.","journal-title":"Blood"},{"key":"1395_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clml.2014.09.004","volume":"15","author":"RS Go","year":"2015","unstructured":"Go RS, Gundrum JD, Neuner JM. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. Clin Lymphoma Myeloma Leuk. 2015;15:177\u201386.e4.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1395_CR8","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41375-019-0419-7","volume":"33","author":"G Goyal","year":"2019","unstructured":"Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, et al. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia. 2019;33:1273\u20137.","journal-title":"Leukemia"},{"key":"1395_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jamaoncol.2015.23","volume":"1","author":"EE Sigurdardottir","year":"2015","unstructured":"Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol. 2015;1:168\u201374.","journal-title":"JAMA Oncol"},{"key":"1395_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/19371910903070333","volume":"25","author":"DS Kim","year":"2010","unstructured":"Kim DS. Introduction: health of the health care system in Korea. Soc Work Public Health. 2010;25:127\u201341.","journal-title":"Soc Work Public Health"},{"key":"1395_CR11","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"1395_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59.","journal-title":"Blood Cancer J"},{"key":"1395_CR13","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","volume":"78","author":"N van Nieuwenhuijzen","year":"2018","unstructured":"van Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V. From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells. Cancer Res. 2018;78:2449\u201356.","journal-title":"Cancer Res"},{"key":"1395_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00480-w","volume":"11","author":"S Rognvaldsson","year":"2021","unstructured":"Rognvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, Oskarsson J, Petursdottir I, et al. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021;11:94.","journal-title":"Blood Cancer J"},{"key":"1395_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105327","volume":"10","author":"H Ko","year":"2025","unstructured":"Ko H, Choi S, Park SS, Jung S, Lee CH, Han S, et al. Quantitative risk of underlying disease conditions for progression from monoclonal gammopathy to multiple myeloma: a nationwide cohort study. ESMO Open. 2025;10:105327.","journal-title":"ESMO Open"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01395-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01395-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01395-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:47:07Z","timestamp":1761821227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01395-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1395"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01395-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Given that the data were anonymized and de-identified, the requirement for informed consent was waived. The study was approved by the Institutional Review Board of Seoul St. Mary\u2019s Hospital, Seoul, Korea (IRB No. KC23ZISI0463) and was conducted in accordance with the Declaration of Helsinki and applicable ethical guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement and patient consent statement"}}],"article-number":"185"}}